How Analysts View Bristol-Myers Squibb after Its 4Q17 Earnings
Wall Street analysts’ estimates
Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ earnings per share (or EPS) estimates and revenues during 4Q17. BMY reported EPS of $0.68 on revenues of $5.5 billion during 4Q17. For fiscal 2017, the company reported EPS of $3.01 on revenues of $20.8 billion.
BMY’s revenue growth was driven by its prioritized brands—including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy—and partially offset by lower sales of its established brands.
Interested in ABBV? Don't miss the next report.
Receive e-mail alerts for new research on ABBV
The chart above shows analysts’ recommendations for Bristol-Myers Squibb stock over the last 12 months.
Analysts’ ratings and recommendations
Bristol-Myers Squibb’s (BMY) stock price has increased ~21.2% over the last 12 months, and it has increased ~2.2% in 2018 year-to-date. Analysts’ estimates show that its stock price may increase ~2.6% over the next 12 months.
Wall Street analysts’ recommendations show a 12-month target price of $64.18 per share compared to its price of $62.63 per share on February 7, 2018.
Of the 23 analysts tracking Bristol-Myers Squibb, ten analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.” The consensus rating for Bristol-Myers Squibb stands at 2.4, which represents a moderate buy for long-term investors and value investors.
The changes in analysts’ estimates and recommendations for BMY are based on changing trends in the company’s performance, recent developments, and changes in its stock price.
Analysts estimate BMY’s forward price-to-earnings (or PE) multiple of 18.8x. Its forward EV-to-EBITDA1 multiple was ~16.1x on February 9, 2018.
Bristol-Myers Squibb’s Orencia is prescribed for the treatment of rheumatoid arthritis. Other drugs for the treatment of various forms of rheumatoid arthritis include AbbVie’s (ABBV) Humira and Johnson & Johnson’s (JNJ) Simponi. Remicade is marketed by Johnson & Johnson (JNJ) in the US and by Merck & Co. (MRK) outside the US market.
- enterprise value to earnings before interest, tax, depreciation, and amortization ↩